Confusion between approved injectable epinephrine products and unapproved nasal solutions has prompted a warning to ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

Rep. Jordan Redman, R-Coeur d’Alene, presented a bill Tuesday to add mifepristone and misoprostol to a list of Schedule IV ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The AHA late Feb. 4 told the administration that its current and proposed tariffs on Canada, Mexico and China may jeopardize ...

Hosted a virtual key opinion leader (KOL) event on November 20, 2024 featuring Abhishek Ray, MD (University Hospitals) and Andrew Webb, PharmD, BCCCP (Massachusetts General Hospital), who discussed ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine. New Drug Application (NDA) Submission Expected in the ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.